AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35842610
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 μg/kg) combined with 30 mL of 0.33% ropivacaine
Trial: 35842610
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 μg/kg) combined with 20 mL of 0.5% ropivacaine
Trial: 32622816
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) followed by Thought Field Therapy (TFT)
Trial: 32144833
Drug: Resveratrol 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 1,000 mg per day for 8 weeks
Trial: 33607312
Drug: Rovalpituzumab tesirine
RxNorm normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rovalpituzumab tesirine (Rova-T) 0.3 mg/kg administered intravenously on day 1 of a 42-day cycle for two cycles.
Trial: 33607312
Drug: Topotecan 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 1.5 mg/m2 administered intravenously on days 1 to 5 of a 21-day cycle.
Trial: 33930787
Drug: RDA diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RDA diet (0.8 g/kg body weight/d)
Trial: 33930787
Drug: 2RDA diet
RxNorm normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2RDA diet (2.0 g/kg body weight/d)
Trial: 34769863
Drug: Oral function
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral function training program
Trial: 32729919
Drug: Algorithm for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm for determining medication count
Trial: 33529783
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) tranexamic acid (TXA) - two 1-g boluses, one prior to tourniquet inflation and one prior to wound closure
Trial: 33529783
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) tranexamic acid (TXA)
Trial: 34578863
Drug: Vitamin D3-enriched
RxNorm normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3-enriched Gouda-type cheese (5.7 μg of vitamin D3)
Trial: 35921235
Drug: FIL 200
RxNorm normalized name: avanafil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIL 200 mg plus MTX
Trial: 35921235
Drug: FIL 100
RxNorm normalized name: avanafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIL 100 mg plus MTX
Trial: 35921235
Drug: FIL 200
RxNorm normalized name: avanafil 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIL 200 mg
Trial: 33855215
Drug: Low carbohydrate
RxNorm normalized name: Low carbohydrate beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low carbohydrate diet (< 100 g carbohydrates/day)
Trial: 33855215
Drug: High carbohydrate
RxNorm normalized name: High carbohydrate food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High carbohydrate diet (> 250 g carbohydrates/day)
Trial: 32623701
Drug: Anti-IBS syrup
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-IBS syrup (15 mL, thrice daily for 6 weeks)
Trial: 32623701
Drug: Placebo syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syrup (similar preparation without plant extract)
Trial: 35723849
Drug: Edaravone 30
RxNorm normalized name: edaravone 30 MG in 100 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone 30 mg by slow intravenous infusion for three days
Trial: 35723849
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (national therapy only)
Trial: 34383325
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with a 980-nm diode laser set at 6.89 W/cm2 energy density, 0.5 W power, and a tip diameter of 10 mm for 15 seconds.
Trial: 33073737
Drug: Ad26.ZEBOV and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.ZEBOV and MVA-BN-Filo two-dose vaccination regimens
Trial: 38552629
Drug: Icosapent ethyl
RxNorm normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Icosapent ethyl (IPE) 4 g/day
Trial: 34578807
Drug: Soy protein-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein-based supplement
Trial: 35012310
Drug: PS-enriched beverage
RxNorm normalized name: PS
DrugBank: Phosphatidyl serine (DB00144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS-enriched beverage (2 g PS/day)
Trial: 36114662
Drug: Brachial artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brachial artery responses during hypercapnia without α₁‐adrenergic receptor blockade (prazosin; 0.05 mg/kg)
Trial: 36114662
Drug: Brachial artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brachial artery responses during hypercapnia with α₁‐adrenergic receptor blockade (prazosin; 0.05 mg/kg)
Trial: 33973307
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab (nivolumab 1 mg/kg i.v. plus ipilimumab 3 mg/kg i.v. every 3 weeks for four cycles, followed by nivolumab 240 mg i.v. every 2 weeks)
Trial: 34590926
Drug: Kyusho Jitsu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kyusho Jitsu intervention (twice a week for 6 months)
Trial: 35509219
Drug: Oral ARD-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ARD-101 (40, 100, and 240 mg)
Trial: 35509219
Drug: Oral ARD-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ARD-101 (240 mg)
Trial: 34479739
Drug: Stem cell
RxNorm normalized name: Stem cells, apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stem cell therapy
Trial: 34487151
Drug: Pradefovir 30
RxNorm normalized name: Pradefovir
DrugBank: Pradefovir (DB15550)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradefovir 30 mg
Trial: 34487151
Drug: Pradefovir 60
RxNorm normalized name: Pradefovir
DrugBank: Pradefovir (DB15550)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradefovir 60 mg
Trial: 35237340
Drug: Loxoprofen sodium
RxNorm normalized name: loxoprofen sodium dihydrate
DrugBank: Loxoprofen (DB09212)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Loxoprofen sodium dispersible tablets
Trial: 32935954
Drug: Motor program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motor program activating therapy (MPAT), 1 hour, twice a week for two months.
Trial: 32935954
Drug: Vojta reflex
RxNorm normalized name: Cuscuta reflexa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vojta reflex locomotion (VRL), 1 hour, twice a week for two months.
Trial: 35081280
Drug: Tofacitinib (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (10 mg twice daily)
Trial: 34370282
Drug: Second-generation antipsychotics
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antipsychotics (SGA)
Trial: 33620516
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of a diagnostic RA code with biologic infusion codes
Trial: 32901996
Drug: 15°C PCM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15°C PCM treatment covering the quadriceps for three hours
Trial: 36048114
Drug: Low dose/preferred
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose/preferred flavor
Trial: 35193609
Drug: Bovine milk-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine milk-based formula containing L. reuteri DSM 17938 at 1 × 10^7 CFU/g (Control Group; CG)
Trial: 35193609
Drug: Bovine milk-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine milk-based formula with added 1.0 g/L 2'FL (Experimental Group; EG)
Trial: 36468967
Drug: 1.4% silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4% silymarin cream
Trial: 32233208
Drug: Compound Amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Amino Acid Capsules (CAAC) combined with clomiphene for 12 weeks
Trial: 33567135
Drug: Subcuticular suturing
RxNorm normalized name: oxytetracycline hydrochloride Oral Tablet [5-Way Calf Scour Bolus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcuticular suturing and early scar management with non‐ablative fractional laser (NAFL) and intralesional triamcinolone injection (ILI)
Trial: 37403410
Drug: L-lactate
RxNorm normalized name: L-lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-lactate
Trial: 32164719
Drug: Compensatory acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compensatory acupuncture therapy (Control)
Trial: 34989824
Drug: Aripiprazole once-monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole once-monthly (AOM) at 400 mg
Trial: 34989824
Drug: Oral aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral aripiprazole at 10-20 mg
Trial: 39316284
Drug: CTC 200
RxNorm normalized name: CTCE-0214
DrugBank: CTCE-0214 (DB05934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC 200 mg BID
Trial: 35974668
Drug: Tramadol 100
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 100 mg QID
Trial: 35174869
Drug: Intensive circuit
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive circuit class therapy
Trial: 37648382
Drug: Second-line therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line therapy
Trial: 32403113
Drug: Third-line therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-line therapy
Trial: 33783006
Drug: Re-treatment with
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-treatment with pan-genotypic DAA (sofosbuvir and velpatasvir with or without ribavirin)
Trial: 34741341
Drug: Dietary mulberry-leaf
RxNorm normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary mulberry-leaf flavonoids (MF) 30 mg/kg
Trial: 34741341
Drug: Dietary mulberry-leaf
RxNorm normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary mulberry-leaf flavonoids (MF) 60 mg/kg
Trial: 36401233
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of triamcinolone acetonide (IVTA) combined with standard phacoemulsification surgery
Trial: 33444116
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC 5) plus Paclitaxel (175 mg/m2) plus Bevacizumab (5 mg/kg) every 2 weeks (CPB arm)
Trial: 33444116
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC 5) plus Paclitaxel (175 mg/m2) without Bevacizumab (CP arm)
Trial: 36473191
Drug: Topical Cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Cyclosporin A 0.1% (CsA), once daily for 12 weeks
Trial: 36473191
Drug: Topical Diquafosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Diquafosol Tetrasodium 3% (DQS), six times a day for 12 weeks
Trial: 36473191
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CsA and DQS, for 12 weeks
Trial: 32919916
Drug: Sacubitril/valsartan therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan therapy
Trial: 35157791
Drug: Domperidone 10
RxNorm normalized name: domperidone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 10 mg 3 times daily
Trial: 35157791
Drug: Domperidone 20
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 20 mg 3 times daily
Trial: 33208340
Drug: Paclitaxel (P)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel (P) weekly × 12 plus carboplatin AUC6 every 21 days × 4 followed by doxorubicin/cyclophosphamide (AC) every 14 days × 4 (CbP → AC, arm A)
Trial: 33452004
Drug: FIL200 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIL200 monotherapy
Trial: 34327739
Drug: GSK3335065 (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3335065 (1.3 mg)
Trial: 32453369
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg orally twice daily for 2 years (n=133)
Trial: 36438801
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg of vancomycin every 12 h
Trial: 36438801
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg of vancomycin every 8 h
Trial: 33188423
Drug: Refined rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refined rice bran, flaxseed, and sesame seed oils (30 g per day for 8 weeks)
Trial: 33963734
Drug: Ready-to-use therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ready-to-use therapeutic food (RUTF) and amoxicillin along with standard nutrition counseling for 2-12 weeks
Trial: 33361021
Drug: MAO‐B inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAO‐B inhibitor (Selegiline 5 mg)
Trial: 33361021
Drug: Donepezil (DNP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (DNP 10 mg daily)
Trial: 33755218
Drug: Chlorhexidine oral
RxNorm normalized name: chlorhexidine Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine oral rinse
Trial: 36435988
Drug: CII elastics
RxNorm normalized name: elastin
DrugBank: Elastin (human) (DB15364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CII elastics (100-150 g/side), full time
Trial: 33556410
Drug: RT +
RxNorm normalized name: CVS Yogurt + Fiber Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT + saffron supplement (150 mg after each session)
Trial: 33556410
Drug: RT +
RxNorm normalized name: CVS Yogurt + Fiber Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT + placebo (dextrose pill)
Trial: 33556410
Drug: RT +
RxNorm normalized name: CVS Yogurt + Fiber Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT + saffron supplement
Trial: 36286887
Drug: Prebiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic treatment (Zacofalk) in subgroup Ia (n=58)
Trial: 32340903
Drug: 16 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 g/d native inulin
Trial: 34436555
Drug: Web-based diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based diet and lifestyle intervention utilizing short animated videos, delivered weekly for 5 weeks.
Trial: 35114186
Drug: 125 cc/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 cc/h normal saline
Trial: 35114186
Drug: 250 cc/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 cc/h normal saline
Trial: 33608403
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of insulin
Trial: 36499011
Drug: Rhubarb extract
RxNorm normalized name: Rhubarb extract
DrugBank: Rhubarb (DB10651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhubarb extract (RE) 12.5 mg per day
Trial: 36499011
Drug: Rhubarb extract
RxNorm normalized name: Rhubarb extract
DrugBank: Rhubarb (DB10651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhubarb extract (RE) 25 mg per day
Trial: 33963015
Drug: Adjuvant ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjuvant ipilimumab 3 mg/kg (ipi3)
Trial: 33963015
Drug: Adjuvant ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjuvant ipilimumab 10 mg/kg (ipi10)
Trial: 35249863
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral anticancer drugs
Trial: 32805594
Drug: Manual milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual milk administration by parents (MAP)
Trial: 32805594
Drug: Electric syringe
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electric syringe administration (ESA)
Trial: 33400237
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) group, n = 11; dose 40 × 10^6 Treg cells/kg of body weight
Trial: 33400237
Drug: Intrathecal (IT)
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal (IT) group, n = 3; dose 1.0 × 10^6 Treg cells
Trial: 32404132
Drug: Robotic rehabilitation
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic rehabilitation using Tymo system or Walker View in addition to traditional therapy
Trial: 35017258
Drug: Analgesic (ANA)
RxNorm normalized name: ANALGESIC CREAM
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic (ANA) treatment (metamizole/dipyrone) with observational learning (positive video)
Trial: 35017258
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo (OLP) treatment with observational learning (positive video)
Trial: 35017258
Drug: Analgesic (ANA)
RxNorm normalized name: ANALGESIC CREAM
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic (ANA) treatment (metamizole/dipyrone) with neutral video
Trial: 35017258
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo (OLP) treatment with neutral video
Trial: 35017258
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no medication or observational learning)
Trial: 32005277
Drug: Adaptive Servo-Ventilation
RxNorm normalized name: Servo Stat Bac
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adaptive Servo-Ventilation (ASV) therapy added to PCI and optimal medical management
Trial: 32005277
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy and PCI alone (control)
Trial: 32130122
Drug: eHealth tool
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eHealth tool with electronic survey and tailored resources for physical activity (PA) prescription
Trial: 33754642
Drug: Ibrutinib (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (420 mg)
Trial: 32348101
Drug: Diosmin 600
RxNorm normalized name: diosmin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diosmin 600 mg once daily for 12 months
Trial: 32348101
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with rivaroxaban for six months and ECS for 12 months
Trial: 36501092
Drug: GTC+CCA (620
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTC+CCA (620 mg GTC, 373 mg CCA, and 119 mg caffeine/day) for three weeks
Trial: 36501092
Drug: PLA (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLA (0 mg GTC, 0 mg CCA, and 119 mg caffeine/day) for three weeks
Trial: 32916291
Drug: Initial conservative
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial conservative strategy (medical therapy)
Trial: 34856913
Drug: Topical ozonated
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ozonated olive oil lotion
Trial: 33253864
Drug: Topical GM-CSF
RxNorm normalized name: axatilimab-csfr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical GM-CSF and miltefosine (G + M)
Trial: 33253864
Drug: Parenteral meglumine
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral meglumine antimoniate (MA)
Trial: 32616150
Drug: Baroreflex Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baroreflex Activation Therapy (BAT) plus optimal medical management
Trial: 35869690
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 1000 mg/m2/day (n = 32)
Trial: 35869690
Drug: Cyclosporine (CYC)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CYC) 5 mg/kg/day (n = 34)
Trial: 33740389
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg GSH per day
Trial: 33230526
Drug: CT-P13 s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P13 s.c. 120 mg biweekly until W28
Trial: 33230526
Drug: CT-P13 i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P13 i.v. 3 mg/kg every 8 weeks until W22